Novavax, Inc. has filed Amendment No. 1 to its Definitive Proxy Statement with the U.S. Securities and Exchange Commission on April 29, 2024, in preparation for its 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. This amendment specifically addresses and clarifies an immaterial aspect of the Amended and Restated 2015 Stock Incentive Plan related to 'Proposal 3 – Amendment and Restatement of the 2015 Stock Plan.' The amendment introduces new compensation limits for non-employee directors, setting a cap of $1,500,000 for the chairman and $1,000,000 for other non-employee directors, with an exception for the year in which a non-employee director begins their service on the Board. The amendment also removes the individual limits on awards granted under the 2015 Stock Plan, which previously restricted the number of shares for stock options, stock appreciation rights (SARs), and other stock awards. This filing does not affect any other items or information presented in the original 2024 Definitive Proxy Statement and should be read in conjunction with it.

Novavax, Inc. has filed Amendment No. 1 to its Definitive Proxy Statement with the U.S. Securities and Exchange Commission on April 29, 2024, in preparation for its 2024 Annual Meeting of Stockholders scheduled for June 13, 2024. This amendment specifically addresses and clarifies an immaterial aspect of the Amended and Restated 2015 Stock Incentive Plan related to 'Proposal 3 – Amendment and Restatement of the 2015 Stock Plan.' The amendment introduces new compensation limits for non-employee directors, setting a cap of $1,500,000 for the chairman and $1,000,000 for other non-employee directors, with an exception for the year in which a non-employee director begins their service on the Board. The amendment also removes the individual limits on awards granted under the 2015 Stock Plan, which previously restricted the number of shares for stock options, stock appreciation rights (SARs), and other stock awards. This filing does not affect any other items or information presented in the original 2024 Definitive Proxy Statement and should be read in conjunction with it.